BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 30365356)

  • 1. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    N Engl J Med; 2019 Jan; 380(5):447-458. PubMed ID: 30365356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose versus low-dose iron sucrose in individuals undergoing maintenance haemodialysis: a retrospective study.
    Liu L; Cheng H; Lv Y; Yu W; Liu Q; Wu Y; Xu B
    BMC Nephrol; 2021 Oct; 22(1):350. PubMed ID: 34706660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
    Mitsopoulos E; Lysitska A; Pateinakis P; Lamprou V; Intzevidou E; Minasidis I; Katsaounou C; Kougioumtzidou O; Anagnostou N; Lemonidis N; Papadopoulou D
    Int Urol Nephrol; 2020 Feb; 52(2):387-392. PubMed ID: 31894555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
    Nguyen TV
    Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.
    Saglimbene V; Palmer SC; Craig JC; Ruospo M; Nicolucci A; Tonelli M; Johnson D; Lucisano G; Williams G; Valentini M; D'Alonzo D; Pellegrini F; Strippoli P; Salomone M; Santoro A; Maffei S; Hegbrant J; Tognoni G; Strippoli GF;
    PLoS One; 2017; 12(3):e0172735. PubMed ID: 28249030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
    Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
    Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.
    Majoni SW; Ellis JA; Hall H; Abeyaratne A; Lawton PD
    Hemodial Int; 2014 Oct; 18(4):740-50. PubMed ID: 24766376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
    Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP
    Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
    Harmankaya O; Eran A
    Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.